I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Kevin Bunker Biography and Net Worth

COO of Zentalis Pharmaceuticals

Kevin is a co-founder and Chief Operating Officer at Zentalis Pharmaceuticals. He leads our R&D team in San Diego. Prior to joining Zentalis, he was a co-founder of Kalyra Pharmaceuticals and currently serves on the board of directors of Kalyra and as its Chief Scientific/Operations Officer. Prior, he was in Pfizer’s drug discovery research group in La Jolla as part of the Medicinal Chemistry Department. He specialized in multiple therapeutic areas including Oncology, Diabetes, Antivirals, and Ophthalmology. Prior to Pfizer, Dr. Bunker carried out postdoctoral research at The Scripps Research Institute under the direction of Professor Dale Boger. He received his PhD in Organic Chemistry from the University of California, San Diego under the direction of Joseph O’Connor and his BS in Chemistry from Arizona State University. He is the inventor on multiple patents and an author of multiple articles in peer-reviewed journals.

What is Kevin D. Bunker's net worth?: The estimated net worth of Kevin D. Bunker is at least $52,050.00 as of May 26th, 2023. Dr. Bunker owns 15,000 shares of Zentalis Pharmaceuticals stock worth more than $52,050 as of November 17th. This net worth approximation does not reflect any other assets that Dr. Bunker may own. Learn More about Kevin D. Bunker's net worth.
How do I contact Kevin D. Bunker?: The corporate mailing address for Dr. Bunker and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Kevin D. Bunker's contact information.
Has Kevin D. Bunker been buying or selling shares of Zentalis Pharmaceuticals?: Kevin D. Bunker has not been actively trading shares of Zentalis Pharmaceuticals in the last ninety days. Most recently, Kevin D. Bunker sold 80,000 shares of the business's stock in a transaction on Friday, May 26th. The shares were sold at an average price of $30.02, for a transaction totalling $2,401,600.00. Following the completion of the sale, the insider now directly owns 15,000 shares of the company's stock, valued at $450,300. Learn More on Kevin D. Bunker's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 10/4/2024.

Kevin D. Bunker Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2023	Sell	80,000	$30.02	$2,401,600.00	15,000
2/13/2023	Sell	3,807	$20.42	$77,738.94	871,657
7/20/2022	Sell	5,000	$30.00	$150,000.00	100,000
7/13/2022	Sell	1,710	$30.02	$51,334.20	108,290
7/5/2022	Sell	25,000	$30.07	$751,750.00	110,000
4/11/2022	Sell	5,000	$30.55	$152,750.00	135,000
3/21/2022	Sell	10,000	$49.07	$490,700.00
3/10/2022	Sell	10,000	$46.94	$469,400.00
2/22/2022	Sell	10,000	$49.09	$490,900.00
2/14/2022	Sell	4,688	$50.26	$235,618.88
2/10/2022	Sell	10,000	$53.50	$535,000.00
1/10/2022	Sell	10,000	$68.41	$684,100.00
12/20/2021	Sell	10,000	$79.24	$792,400.00
12/10/2021	Sell	10,000	$71.71	$717,100.00
11/22/2021	Sell	10,000	$75.99	$759,900.00
11/10/2021	Sell	10,000	$78.15	$781,500.00
10/1/2021	Sell	8,420	$66.13	$556,814.60
9/1/2021	Sell	8,420	$67.49	$568,265.80	994,841
8/2/2021	Sell	8,420	$51.05	$429,841.00	994,841
7/6/2021	Sell	20,298	$46.90	$951,976.20	1,014,747
7/1/2021	Sell	8,420	$51.23	$431,356.60	1,019,653
6/1/2021	Sell	8,420	$54.09	$455,437.80	1,019,653
5/3/2021	Sell	8,420	$59.24	$498,800.80	1,019,653
4/13/2021	Sell	3,810	$45.00	$171,450.00	1,019,653
4/5/2021	Sell	24,536	$43.37	$1,064,126.32	1,035,440
4/1/2021	Sell	4,210	$43.45	$182,924.50	1,044,464
3/10/2021	Sell	4,720	$45.24	$213,532.80
3/3/2021	Sell	3,700	$45.07	$166,759.00
1/4/2021	Sell	26,567	$52.08	$1,383,609.36	1,052,280
12/7/2020	Sell	10,892	$53.52	$582,939.84	1,071,305
12/4/2020	Sell	12,165	$50.98	$620,171.70	1,071,305
12/1/2020	Sell	8,420	$52.96	$445,923.20	1,076,937
11/23/2020	Sell	8,425	$46.55	$392,183.75
4/7/2020	Buy	350	$18.00	$6,300.00

Kevin D. Bunker Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $3.47

$3.36

$4.00

50 Day Range

MA: $3.42

$2.70

$4.36

2 Week Range

Now: $3.47

$2.66

$18.07

Volume

1,832,087 shs

Average Volume

1,566,191 shs

Market Capitalization

$247.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

I was wrong. Dead wrong.

From Porter & Company | Ad